氨磷汀联合CHG方案治疗高危骨髓增生异常综合征疗效观察  

Effect of amifostine plus CHG regimen on high-risk myelodysplastic syndromes

作　　者：张诚[1] 

机构地区：[1]南阳医学高等专科学校第一附属医院血液科,河南南阳473000

出　　处：《中华实用诊断与治疗杂志》2014年第12期1243-1244,共2页Journal of Chinese Practical Diagnosis and Therapy

摘　　要：目的观察氨磷汀联合CHG方案(阿糖胞苷+羟基喜树碱+重组人粒细胞刺激因子)治疗高危骨髓增生异常综合征(myelodysplastic syndromes,MDS)的疗效。方法 31例高危MDS患者,依据国际预后评分分为中危Ⅱ组16例和高危组15例,2组均应用氨磷汀联合CHG方案治疗,14d为1个周期,治疗4个周期后评估疗效,随访观察患者生存时间。结果 31例均完成4个周期治疗,中危Ⅱ组总有效率(81.25%)与高危组(80.00%)比较差异无统计学意义(P>0.05),完全缓解率(31.25%)高于高危组(20.00%)(P<0.05);中危Ⅱ组2a生存率(37.50%)高于高危组(26.67%)(P<0.05);中危Ⅱ组血液学毒性反应发生率(37.50%)、感染发生率(56.25%)、恶心呕吐发生率(31.25%)与高危组(33.33%、53.33%、33.33%)比较差异无统计学意义(P>0.05)。结论氨磷汀联合CHG方案治疗高危MDS安全有效,对中危Ⅱ组患者有较好的完全缓解率及生存改善。Objective To observe the effect of amifostine plus CHG regimen（cytarabine＋hydroxycamptothecin＋recombinant human granulocyte colony stimulating factor）on high-risk myelodysplastic syndromes.Methods Thirty-one patients with high-risk myelodysplastic syndromes were divided into intermediate-risk-Ⅱ group（n=16）and high-risk group（n=15）according to International Prognostic Scoring System（IPSS）score.Both two groups were treated by amifostine plus CHG regimen,for 14 days as a cycle.The efficacy was evaluated after 4cycles and the survival time was followed up.Results All patients accomplished 4cycles.There was no significant difference in the total effective rate between intermediate-risk-Ⅱ group（81.25%）and high-risk group（80.00%）（P〉0.05）.The complete remission rate was higher in intermediate-risk-Ⅱ（31.25%）than that in high-risk groups（20.00%）（P〈0.05）.The 2-year survival rate was higher in intermediate-risk-Ⅱ group（37.50%）than that in high-risk group（26.67%）（P0.05）.There were no significant differences in the incidences of hematopoietic suppression,infection,and nausea and vomitting between intermediate-risk-Ⅱ group（37.50%,56.25%,31.25%）and high-risk group（33.33%,53.33%,33.33%）（P〉0.05）.Conclusion Amifostine plus CHG regimen is safe and effective for high-risk myelodysplastic syndromes,and has agood complete remission and survival improvement effect on patients with intermediate-risk-Ⅱ myelody splastic syndromes.

关 键 词：骨髓增生异常综合征 氨磷汀 CHG方案 

分 类 号：R551.3[医药卫生—血液循环系统疾病]